Total Cohort* |
1569 |
|
|
|
|
|
|
Unvaccinated |
415 |
24745 |
8 |
3 |
|
|
|
≥14d from 2nd dose |
1476 |
172457 |
64 |
4 |
16.6 |
(-75.3; 60.3) |
29.0 (-51.4; 66.7) |
Total Cohort, excluding participants with PCR-confirmed
infection prior to enrolment** |
1327 |
|
|
|
|
|
|
Unvaccinated |
253 |
36012 |
8 |
2 |
|
|
|
≥14d from 2nd dose |
1268 |
304360 |
61 |
2 |
36.8 |
(-32.7; 69.9) |
*** |
DELTA PERIOD (1/07/21-12/1/21) |
|
|
|
|
|
|
|
Total Cohort* |
1565 |
|
|
|
|
|
|
Unvaccinated |
293 |
17105 |
7 |
4 |
|
|
|
≥14d from 2nd dose |
1478 |
147488 |
62 |
4 |
5.6 |
(-108; 57.1) |
19.1
(-80.7; 63.8) |
Total Cohort, excluding participants with PCR-confirmed
infection prior to enrolment** |
1322 |
|
|
|
|
|
|
Unvaccinated |
181 |
21634 |
7 |
3 |
|
|
|
≥14d from 2nd dose |
1266 |
248951 |
59 |
2 |
28.6 |
(-57.2; 67.6) |
*** |